Let’s start up with the current stock price of Revance Therapeutics, Inc. (RVNC), which is $23.24 to be very precise. The Stock rose vividly during the last session to $24.11 after opening rate of $23.4 while the lowest price it went was recorded $22.58 before closing at $23.17.
Revance Therapeutics, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $27.97 on 02/21/20, with the lowest value was $9.88 for the same time period, recorded on 08/28/19.
Revance Therapeutics, Inc. (RVNC) full year performance was 97.79%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Revance Therapeutics, Inc. shares are logging -16.91% during the 52-week period from high price, and 135.22% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $9.88 and $27.97.
The company’s shares, operating in the sector of healthcare managed to top a trading volume set approximately around 856996 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Revance Therapeutics, Inc. (RVNC) recorded performance in the market was 43.19%, having the revenues showcasing 77.40% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.32B, as it employees total of 193 workers.
Market experts do have their say about Revance Therapeutics, Inc. (RVNC)
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 19.91, with a change in the price was noted +0.90. In a similar fashion, Revance Therapeutics, Inc. posted a movement of +4.03% for the period of last 100 days, recording 772,924 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity. The total Debt to Equity ratio for RVNC is recording 0.56 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.56.
Technical breakdown of Revance Therapeutics, Inc. (RVNC)
Raw Stochastic average of Revance Therapeutics, Inc. in the period of last 50 days is set at 90.95%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 76.86%. In the last 20 days, the company’s Stochastic %K was 82.01% and its Stochastic %D was recorded 74.54%.
Bearing in mind the latest performance of Revance Therapeutics, Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 43.19%. Additionally, trading for the stock in the period of the last six months notably improved by 42.58%, alongside a boost of 97.79% for the period of the last 12 months. The shares increased approximately by 15.02% in the 7-day charts and went down by 8.62% in the period of the last 30 days. Common stock shares were driven by 77.40% during last recorded quarter.